Risk Stratification in Brugada Syndrome: Current Status and Emerging Approaches by Honarbakhsh, S et al.
 1 
 
 
 
 
Risk stratification in Brugada Syndrome – Current Status and Emerging 
Approaches 
 
Honarbakhsh S* MRCP BSc, Providencia R* MD PhD, Lambiase PD* PhD FRCP 
FHRS 
 
*The Barts Heart Centre, Barts Health NHS trust, Department of Electrophysiology, 
London, United Kingdom  
Word count: 2259 
 
 
Corresponding Author: 
Professor Pier D Lambiase PhD FRCP FHRS  
Professor of Cardiology and Consultant Electrophysiologist 
Institute of Cardiovascular Science, UCL 
The Barts Heart Centre, West Smithfield 
London EC1A 7BE 
Tel & Fax: +44 208 357 1319  
Tel: +44 203 456 4407  
Fax: +44 207 573 8838 
 
 2 
Brugada syndrome (BrS) remains one of the most common inherited channelopathies 
associated with an increased risk of sudden cardiac death (SCD), with a worldwide 
prevalence of approximately 0.05% (1-3). It is accepted that appropriate utilization of 
the ICD in high-risk patients with aborted SCD and haemodynamically compromising 
arrhythmias is life saving. However, there remains a lack of consensus on the 
management of patients with BrS and no history of ventricular arrhythmias or aborted 
SCD especially in the context of a resting Type 1 coved ECG pattern. The current 
guidelines (4) and consensus statement (5) recommend ICD implantation in patients 
with BrS with spontaneous type 1 ECG pattern and probable arrhythmic-related 
syncope, the latter being heavily dependent on the quality of the syncope history. This 
recommendation is based on several studies having demonstrated a higher risk of 
arrhythmic events in such patients compared to those without these factors present (2, 
3, 6, 7). However, whether other clinical factors are better predictors or facilitate more 
refined risk stratification before any arrhythmic event is still up for debate. This is 
especially important, as the first clinical event may be cardiac arrest. Indeed, the 
recent SABRUS study that specifically evaluated patients presenting with a lethal 
arrhythmic event found 25% of patients did not reach the current ICD implantation 
criteria (8).  
 
i) Brugada ECG pattern or BrS 
Before refining risk stratification strategies, it is important to clarify what establishes 
a diagnosis of BrS. Guidelines recommend that the presence of a type 1 Brugada ECG 
pattern whether drug-induced or spontaneous (4, 5). However, others argue that 
without the presence of symptoms the ECG features only indicate the presence of a 
Brugada pattern ECG and not the syndrome itself. This argument stems from the 
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yearly cardiac event only being 0.5% in these patients compared to a yearly cardiac 
event rate of 1.9% in patients with a history of syncope (3). With the annual risk of 
death from any cause being around 0.4% in the middle aged male population most 
commonly affected (9), the additional risk of BrS induced cardiac arrest appears 
minimal in the asymptomatic population (10). Therefore it can be argued that labeling 
patient with only a type 1 Brugada ECG pattern and no symptoms with a syndrome 
and proposing that they are at a significant enhanced risk of SCD might be 
inappropriate. Offering advise on the aggressive treatment of a fever, avoidance of 
type 1 ECG pattern provoking drugs and offering review in the presence of symptoms 
may be sufficient for this cohort of patients. This is supported by the up-to-date 
guidelines that provide a class I recommendation for observation without therapy in 
these patients (4). However, there is a spectrum of risk. Sacher F et al. (10) showed 
that 12% of BrS patients that were asymptomatic at ICD implantation had appropriate 
ICD therapy during a 10-year follow-up period. Further to this, the presence of 
spontaneous type 1 ECG pattern alone has been shown to be associated with a lower 
cumulative survival (2), twice the risk of arrhythmic events (3, 11, 12) and shorter 
time to first arrhythmic event (3) compared to drug-induced type 1 ECG pattern. 
Therefore, the diagnosis of an isolated Brugada ECG pattern should potentially be 
restricted to those patients with only drug-induced type 1 ECG pattern and exclude 
those with a spontaneous type 1 ECG pattern. Furthermore, as the presence of both 
spontaneous type 1 ECG pattern and syncope has been shown to be associated with a 
significantly higher risk of cardiac arrest compared to spontaneous type 1 ECG 
pattern alone, those with the former should potentially be labeled as a high-risk group 
whilst the latter an intermediate-risk group (3).  
 
 4 
ii) Ajmaline testing 
Another area that requires clarification is the use of Ajmaline testing. Ajmaline is 
used to provoke the presence of a type 1 Brugada ECG pattern. Along the same lines 
as already discussed, the presence of a provoked type 1 ECG pattern in the absence of 
symptoms is not associated with a significant risk of SCD-0.3%/3 years (3). This 
raises the question of whether performing this investigation is appropriate if it will not 
result in a change in patient management and might not only lead to enhanced patient 
anxiety but also unnecessary risk associated with ajmaline testing. This is of 
particularly importance as studies have reported high rates of concealed type 1 
Brugada ECG pattern in asymptomatic patients (13) and should thereby all of these 
patients be labeled with a syndrome that has life-long implications? 
 
However, if patients are symptomatic, ajmaline testing should be warranted due to the 
increased risk of SCD seen in these patients with BrS (10). Further to this, in those 
with a family history of SCD in first-degree relatives, ajmaline testing can help to 
explain the cause of death in the proband but also if positive allows the identification 
of family members with potential high-risk features (5).  
 
iii) Risk Stratification in BrS 
Identifying factors that are associated with an increased risk of ventricular 
arrhythmias and SCD in BrS is now a significant challenge. With ICDs being 
associated with a life-long complication risk of up-to 45% (14) it is essential that the 
decision to implant these devices be not taken lightly.  Indeed, although the advent of 
subcutaneous ICDs could reduce the risk of transvenous lead problems long-term; 
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there still remains the morbidity of inappropriate device therapies and risks of 
infection with multiple generator changes over time. 
 
Several risk factors have been proposed over the years. The FINGER registry, the 
largest international cohort to date assessed the role of 6 proposed risk factors: 
syncope, spontaneous type 1 ECG, gender, family history of SCD, inducibility of 
ventricular tachyarrhythmias during electrophysiological study and presence of an 
SCN5A mutation in predicting ventricular arrhythmic events. Syncope and 
spontaneous type 1 ECG pattern were the only significant predictors (3). These 
factors are the only ones that continue to remain consistent in their predictive role as 
shown in other studies (3, 6, 15, 16). Other markers however, either yield conflicting 
data or have only been assessed in a small proportion of studies making it difficult to 
evaluate their true role in the risk stratification of Brugada patients (Table 1). 
 
a) Factors with conflicting evidence 
A positive programmed electrical stimulation test is a good example of one of these 
factors in this pool of conflicting evidence whereby it has been shown to be a strong 
predictor of ventricular arrhythmias in BrS in some studies (15, 16) whilst many have 
shown that it plays no role in BrS risk stratification (3, 6, 17, 18). Recent data from 
the FINGER Registry suggests a positive study with up to 2 extrastimuli could have 
prognostic significance, and a negative study has a high negative predictive value 
(15). The presence of an SCN5A mutation (3, 6, 15, 17) and family history of SCD (3, 
15, 17) are further factors which role in risk stratification of Brugada patients remains 
conflicting. Based on these findings utilizing programmed electrical stimulation and 
genetic mutation testing in the risk stratification of these patients would not be 
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strongly recommended on a population level unless there is a particularly malignant 
family history or specific highly arrhythmogenic mutations.  
 
b) ECG markers with promising predictive value 
The presence of type 1 Brugada pattern in peripheral leads (18), early repolarization 
(ER) (19-22), avR sign (23) and S wave in lead 1 (17), fragmented QRS (24) (Figure 
1) have shown to be associated with an increased risk of ventricular arrhythmia 
occurrence during follow-up. However, as these factors have not been consistently 
assessed in a range of studies it is unclear whether their predictive value applies 
across a general BrS population. The presence of ER has already been associated with 
a higher risk of ventricular arrhythmic events in patients with idiopathic ventricular 
fibrillation (25, 26) and it is thereby possible that its presence indicates an 
arrhythmogenic predisposition. It is plausible that the presence of type 1 Brugada 
pattern in peripheral leads is indicative of a higher “Brugada substrate burden” and as 
a result associated with a greater risk of ventricular arrhythmia occurrence. Evaluating 
all these factors together in a large BrS population is required to effectively establish 
their importance.  
 
c) Risk scoring model in Brugada syndrome 
A number of studies have combined risk factors to predict risk of sudden death (11, 
16, 27). The initial study by Delise et al. (11) showed that no single risk factors was 
able to identify Brugada patients at high risk of arrhythmic events and that a multi-
parametric approach was a more robust strategy. They showed that subjects at highest 
risk were those with a spontaneous type 1 ECG pattern and at least 2 further risk 
factors (including syncope, family history of SCD and positive programmed electrical 
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stimulation). The recent study by Sieira J et al. (16) evaluated several factors and 
proposed a score that included the presence of 1) spontaneous type 1 ECG pattern, 2) 
early familial SCD (<35 years old), 3) positive programmed electrical stimulation, 4) 
presentation as syncope or as aborted SCD and 5) sinus node dysfunction and 
demonstrated a predictive performance of 0.82 for this score. They showed that a 
score greater than 2 conferred a 5-year event probability of 9.2%. However, it is 
important to consider several points prior to implementing the use of this score. The 
factors utilized in this risk score were derived only from univariate analysis. Since no 
multivariate analysis was conducted, it is unclear whether all these factors have an 
independent predictive role for ventricular events. Furthermore, the validation of the 
risk score that established its predictive performance was undertaken in a cohort from 
the same centre. Since this risk score has not yet been evaluated externally and the 
baseline characteristics of the cohort used in this study showing several differences to 
other larger studies it is unclear whether this predictive performance is applicable to a 
general BrS population. Therefore, even though this approach of integrating risk 
factors is promising, further validation in several BrS is warranted prior to its use in 
clinical practise. There is clearly a role for combined risk factor scoring in BrS.  
 
iv) The Future in BrS 
Several studies have demonstrated prolonged RVOT activation with marked regional 
conduction delay and fractionated late potentials in patients with BrS (17, 24, 28). As 
well as utilizing clinical derived clinical risk factors in risk stratification, there may be 
a role for more refined evaluation of the arrhythmogenic substrate. ECG imaging 
(ECG-I) has demonstrated marked conduction delays in the right ventricular outflow 
tract (RVOT) and this area of delay is expanded in the presence of ajamline (29). The 
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degree and/or area of delay may be another useful biomarker to predict risk-indeed an 
ECG-I approach to risk has been proposed in a preliminary study utilizing exercise 
stress (30). Although genetic factors are important, their role to date has been limited 
to individual mutations-the burden of specific variants may also be utilized in the 
future to refine risk scoring. 
 
The current American College of Cardiology, American Heart Association, and Heart 
Rhythm Society Guideline for Management of Ventricular Arrhythmias recommend 
catheter ablation or quinidine for: a) patients experiencing recurring shocks for 
ventricular arrhythmias, and b) for patients with spontaneous type 1 pattern and 
symptomatic ventricular arrhythmias who either are not candidates for an ICD or 
decline an ICD (class of recommendation: I; Level of evidence “B – non-randomized 
for both”) (31). Two studies have shown that with epicardial catheter ablation 
performed in the RVOT, with a view of eliminating this arrhythmogenic 
electrophysiological substrate resulted in the normalization of the Brugada ECG in 
majority of patients even after ajmaline (32, 33). In the study with the larger cohort of 
patients (32) the current follow-up is less than a year therefore a longer follow-up 
period is required to ensure that the ablation effect is permanent. Indeed a clinical trial 
is now in progress to evaluate the role of prophylactic ablation in BrS (Clinical trial 
registration- NCT02641431)– however, given the fact that the condition may be a 
progressive disease issues relating to risk stratification even after ablation will remain 
with us for the foreseeable future.   
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Table 1- The studies that have evaluated factors in their role in predicting ventricular 
arrhythmia occurrence and/or SCD during follow-up in patients with Brugada 
syndrome.  
 
Studies Factors assessed  Predictive risk factors 
HR (95% CI)* *  
 
Follow-up 
Median (range) 
Mean ± SD 
Probst V et al. 2010 (3) Syncope  
 
Spontaneous type 1 ECG 
 
Male gender 
SCN5A mutation +ve 
Family history of SCD* 
PES^ +ve 
Yes  
3.4 (1.6-7.4), p=0.002 
Yes 
1.8 (1.03-3.33), p=0.04 
No 
No 
No 
No 
31.9 months (14-54.4) 
Priori SG et al. 2012 (6) Spontaneous type 1 ECG 
+Syncope  
QRS fragmentation 
 
VRPŢ<200ms 
 
PES +ve 
Yes 
4.20 (1.38-12.79), p=0.012 
Yes 
4.94 (1.54-15.8), p=0.007 
Yes 
3.91 (1.03-12.79), p=0.045 
No 
36 ± 8 months 
 
Sroubek J et al. 2016 (15) PES +ve Yes 
2.66 (1.44-4.92), p<0.001 
38 months (20.9-60.3) 
Sieira J et al. 2017 (16) Syncope 
 
Spontaneous type 1 
 
Male gender 
 
Sinus node dysfunction 
 
PES +ve 
 
Proband status  
 
QRS duration >120ms 
 
Family history of SCD 
Yes 
3.7 (1.6–8.6), p<0.01 
Yes 
2.7 (1.3–5.4), p<0.01 
Yes 
2.7 (1.2–6.2), p=0.02 
Yes 
5.0 (1.5–16.3), p<0.01 
Yes 
4.7 (2.2–10.2), p<0.01 
Yes 
2.1 (1.0–4.200, p=0.04 
Yes 
1.03 (1.01–1.04), p<0.01 
No 
0.6 (0.3–1.3), p=0.20 
80.7 ± 57.2 months 
Calo L et al. 2016 (17) S wave pattern in lead 1 
 
Presence of AF 
 
Yes 
39.1 (5.34-287.10), p<0.0001 
Yes 
3.70 (1.59-8.73), p=0.0024 
48 ± 38.6 months 
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Male gender 
Family history of SCD 
First degree heart block 
QTc prolongation 
Early repolarization 
Epsilon wave present 
QRS fragmentation 
QRS duration >120ms 
SCN5A mutation +ve 
PES +ve 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Kamakura S et al. 2009 (19) Family history of SCD 
 
Early repolarization  
 
Spontaneous type 1 ECG 
PES +ve 
Yes 
3.28 (1.42-7.60), p=0.005 
Yes 
2.66 (1.06-6.71), p=0.03 
No 
No 
48.7 ± 14.9 months 
Tokioka K et al. 2014 (22) Syncope  
 
QRS fragmentation 
 
Early repolarization 
Yes  
28.57 (6.14-142.86), <0.001 
Yes  
5.21 (1.69-16.13), p=0.004 
Yes 
2.87 (1.16-7.14), p=0.023 
45.1 ± 44.3 months 
 
  
* *Multivariate analysis except Sieira J et al. (16) 
which is univariate analysis  
*SCD- sudden cardiac death 
^PES- programmed electrical stimulation 
ŢVRP- ventricular refractory period 
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FIGURE LEGEND 
Figure 1A-D- Demonstrates proposed ECG markers that have shown to have role in 
predicting ventricular arrhythmias in Brugada syndrome A) Type 1 Brugada pattern in 
peripheral leads B) avR sign (dominant R wave in avR) C) Early repolarization (ST 
elevation in the inferolareral leads) D) S wave in lead I. 
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